In 1906, Paul Ehrlich made a prophecy regarding the role of modern-day pharmaceutical research. He predicted that chemists would soon be able to produce substances that would seek out specific disease-causing agents. He referred to these substances as 'magic bullets'.

At Vivolux we believe in the methodology and creativity of Ehrlich although since his time chemical know-how and the instruments found in pharmaceutical laboratories have advanced considerably. By combining creativity with expert knowledge in organic chemistry, biochemistry, clinical pharmacology, mechanism of action studies and experimental and clinical oncology Vivolux is playing an active part in developing the magic bullets predicted by Ehrlich. Achieving success in the search for a 'magic bullet' in cancer therapy is now greater than ever.

Research groups all over the world have begun to discover the potential of Vivolux services. This approach has lead to the identification and lead optimization of several interesting classes of novel compounds.

 

PRESS RELEASE October 7, 2014 - VLX1570 FDA clearance » More

PRESS RELEASE April 14, 2014 - FDA gives clearance to proceed with clinical study - new drug candidate from Vivolux starves cancer cells
» More

PRESS RELEASE - New drug candidate from Vivolux starves cancer cells. February 18, 2014
» More

Blood abstract. December 6, 2013
» More

PRESS RELEASE - Multiple myeloma first indication for drug candidate from Vivolux Blood publishes study on drug candidate for multiple myeloma that overcomes drug resistance by new mechanism of action. December 6, 2013
» More

Inhibition of proteasome deubiquitinating activity as a new cancer therapy, Nature Medicine November 6, 2011
» More

Nature Medicine publishes study on new mechanism of action for cancer drug
» More

Inhibition of proteasome deubiquitinating activity as a new cancer therapy, Nature Medicine November 6, 2011
» More

Nature Medicine publishes study on new mechanism of action for cancer drug
» More

Favorable results with Vivolux iron chelator VLX 50 in primary ovarian carcinoma cultures published in Biochemical Pharmacology (April 22, 2011).
» More

Vivolux Inc., 20130 Lakeview Center Plaza, Suite 400, Ashburn, VA 20147, USA